Natixis is committed to cancer research
On the occasion of World Cancer Day on February 4th, Natixis reviews its commitment to the Gustave Roussy Foundation.
Since 2011, Natixis has supported the Gustave Roussy Foundation with its cancer research. After supporting three research teams working on personalized cancer treatments, Natixis once again pledged its support in 2016 by offering financial support to three new research teams for their work in immunology, precision medicine and DNA repair : three main lines of research against cancer.
Gustave Roussy, Europe's leading ca,cer research center, has always closely associated care with fundamental and clinical research, giving it world-renowned expertise in the field of therapeutic innovation in oncology.
In 2017, Natixis conducted several mobilization actions to support Gustave Roussy. Natixis has been a partner in two events proposed by Gustave Roussy: a concert organized at the Salle Gaveau in aid of the fight against ovarian cancer and a digital campaign conducted on the occasion of Pink October, movement promoting breast cancer awareness. Natixis has also joined forces with Gustave Roussy and Racing 92 - which it has been official sponsor for 10 years- to support Movember, the international yearly men’s health event.
True to its engagement in the fight against cancer, Natixis pledges to cease its financing and investment activities linked to the tobacco industry worldwide. Natixis is committed to end all financing and investment in favor of tobacco producers, wholesalers and traders, as well as tobacco product manufacturers.
“Tobacco is a major public health issue worldwide. As a committed sponsor of Fondation Gustave Roussy, Natixis already makes a significant contribution to treating and preventing cancer. By excluding tobacco from our financing and investment activities, we are reinforcing our engagement with civil society”, explains Laurent Mignon, Chief Executive Officer of Natixis.